NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVES

Abstract: The present invention relates to the novel quinolone carboxylic acid derivatives of formula (I) and their pharmaceutically acceptable salts and their hydrates. In said formula, X is a hydrocarbon, fluorocarbon or nitrogen atom, Y is a hydrogen or methyl group, R<1> is a hydrogen or alkyl group having 1 to 5 carbon atom, R<2> is (a) (wherein A and B are a fluorocarbon or nitrogen atom, provided that, if A=CF, B=N and if A=N, B=CF) and R<3> is (b) (wherein R<4> is an amino group which makes a racemate or (S)-enantiomer) or (c) (wherein R<5>, R<6> and R<7> are respectively hydrogen or alkyl group having 1 to 3 carbon atom). The quinolone carboxylic acid derivative of formula (I) is prepared by the condensation of the compound of formula (II) and the compound of formula HR<3> in a solvent in the presence of an acid-acceptor or an excess of the compound of formula HR<3> which is a reactant; and the solvent is selected from the group consisting of pyridine, acetonitrile and N,N-dimethylformamide. In formula (II) and HR<3> X, Y, Z, R<1>, R<2> and R<3> are each as described. The compounds according to the present invention are used for antibacterial agent.

Description: NOVEL QUINOLONE CARBOXYLIC ACID DERIVATIVES BACKGROUND OF THE INVENTION The present invention relates to the novel quinolone carboxylic acid derivatives, their esters, their pharmaceutically acceptable salts and their hydrates as shown in formula (I) and a process for preparing these compounds. Furthermore, some of the invented quinolone carboxylic acid derivatives as shown in fornula (I) show broad spectrum and excellent pharraacokinetic properties and low toxicity. Wherein X is a hydrocarbon, fluorocarbon or nitrogen atom, Y is a hydrogen or methyl group, R 1 is a hydrogen or C1-C5 alkyl group, R 2 is ^ ^ ^ (wherein A and B are fluorocarbon or nitrogen atom, (wherein R 4 is an amino group to make a racemate or (S) -enantiomer.) or (wherein R 5 , R 6 and R 7 are Ci- C3 alkyl groups.) In general, most of the quinolone-type antibiotics which have been heretofore developed are ones having small alkyl and cycloalkyl group at N-l position [e.g. Norfloxacin : IBP 4,146,719, Ciprofloxacin : USP 4,620,007 ] and ones having aromatic group at N-l position [e.g. Temafloxacin : J. Med. Chem., 34, 168 (1991), Tosufloxacin : USP4.704.459]. However, a noticeable quinolone antibiotic having heteroaromatic group at N-l position has not been yet developed. Otsuka, Toyama and others reported their researches upon introducing heteroaromatic group such as furyl, thienyl, thiazol, imidazol, pyridyl, pyriraidyl group at. N-l position, but a compound available in vivo has not been yet developed. (JPK 61-251667-A, 62-174053-A, 02-85255-A). In particular, the compounds developed up to now generally have good in vitro activity, but such in vitro activity could not leads to in vivo because of poor pharmacokinetics including half-life(tι/2), maximum blood level(Cmax), bioavilability (BA), area under curve(AUC) etc, which are important, properties of a compound for good in vitro activity to be maintained in vivo. Therefore, the object of this invention is to develope compounds having excellent pharmacokinetic properties by introducing fluoro pyridyl group which is a heteroaromatic group at N-l position, thereby to produce compounds having good antibiotic power in vivo and long half-life(tι/2) which enable once a day of dose. Therefore, the present invention provides a series of compounds having even more excellent pharmacokinetic properties than those of the conventional quinolone antibiotics by introducing 5-fluoro-2-pyridyl group and 3-fluorc—4-pyridyl group into mother nuclei of quinolone and naphthyridine. SUMMARY OF THE INVENTION The present invention relates to novel quinolone carboxylic acid derivatives which have a f1uoropyridine group at N - 1 position. The object of the present invention is to provide the novel quinolone carboxylic acids, their esters, their pharmaceutically acceptable salts, and their hydrates in which are some compounds having broad spectrums, excellent pharmacokinetic properties and low toxicity which are important factors for a drug to be administrated and function in the body, and a process for preparing these compounds. Some of these quinolone derivatives have longer half-life(tι/2), even higher maximum blood level(Cmax) and bioavailability(BA) and even larger area under curve (AUC) compared to ciprofloxacin of the prior art. In addition, they have still far longer half-life(tι/2> and larger area under curve (AUC) compared to ofloxacin which is known to have excellent pharmacokinetics. Accordingly, some of the novel quinolone carboxylic acid derivatives of the present invention are expected to have highly increased in vivo activity. DETAILED DESCRIPTION OF THE INVENTION Wherein X is a hydrocarbon, fluorocarbon or nitrogen atom, Y is a hydrogen or methyl group, R 1 is a hydrogen or C1-C5 alkyl group, R 2 is /■-. —^ (wherein A and B are fluorocarbon or nitrogen atom, (wherein R 5 , R 6 and R 7 are Ci- C3 alkyl groups.) The compound of the formula (I) can be prepared as follows. Each compound in the formula (I) is prepared by the substantially same method except the reaction temperature, irrespective of the kind of X, Y, Z in the compound of the formula (II) (VI) (I ) Wherein X, Y, Z, R ' , R 2 and R 3 are each as described above. The above reaction is carried out in a solvent selected from the alcohols such as methanol, ethanol, the ethers such as tetrahydrofuran, dioxane, 1,2- dimethoxyethane, diglyme, aromatic hydrocarbons such as benzene, toluene, xylene, and the inert, solvents such as acetonitrile, N,N-dimethylformamide, dimethyl suIfoxide, pyridine etc., at 0 °C to 150 °C temperature for 5 minutes to 48 hours. In addition, the above reaction is generally carried out in the presence of an acid-acceptor, the desirable amount of which is 1 to 3 equivalent of the compound (II). Alternatively, an excess of the compound (VI) may be used as an acid- acceptor. As an acid-acceptor, a tertiary amine such as pyridine, triethylamine or l,8-diazabicyclo[5.4.0] undec-7-ene, or an alkali metal carbonate such as sodium hydrogen carbonate, sodium carbonate or potassium carbonate may be used. In order to prepare the compound of the formula (I) wherein R 1 is a hydrogen, the compound of the formula (II") (wherein R 1 is a hydrogen) and HR 3 of the formula (VI) (wherein R 3 is the same as described above) can be reacted; or otherwise the compound of the formula (II') (wherein R 1 is an alkyl group) and HR 3 of the formula(VI) (wherein R 3 is the same as described above) can be reacted first and then hydrolysis using an acid or alkali can be carried out. At this time, in the acidic hydrolysis may be used an acid such as hydrochloric acid and sulfuric acid and in the alkaline hydrolysis may be used an alkali such as sodium hydroxide and potassium hydroxide. The acid or alkali may be used in the hydrolysis as a solution in water or water-containing ethanol or methanol. The compound of the formula (II) can be prepared as follows. (II = II * +11") ( III ) (IV) (V) (ID (II") Wherein X, Y, Z, R 1 and R 2 are each as defined above. The compound of the formula (III) is prepared by the conventional method [Ger. Offen. DE 3, 142, 854; Ger. Offen. DE 3, 318, 145 ; J. Med. Chem., 29, 2363(1986)] and thereby obtained compound of the formula (III) is reacted with the compound of the formula(IV) prepared by the conventional method [Rocz. chem., 38, 777-783(1964); Synthesis, 12, 905-908(1989)] in an alcohol solvent such as methanol and ethanol, or a haloformic solvent such as dichloromethane and chloroform at -10 °C - 30"C to obtain the compound of the formula (V). The obtained compound of the formula (V) is subjected to a ring-closing reaction using potassium carbonate and 18-crown-6 in acetonitrile, or a ring-closing reaction using sodium hydride in N.N-dimethyl formaraide, to obtain the compound of the formula (II'). At this time the reaction temperature is desirably from 0"C to the reflux temperature. The compound of the formula (II' ) is hydrolyzed by treatment with an acid or alkali to obtain the compound of the formula (II") and the compounds of the formula (II') and (II") are designated totally as the formula (II). At this time, in the acidic hydrolysis may be used an acid such as hydrochloric acid or sulfuric acid, and in the alkaline hydrolysis may be used an alkali such as sodium hydroxide or potassium hydroxide. The acid or alkali may be used in the hydrolysis as a solution in water or water-containing ethanol or methanol. Representati e examples of the novel quinolone carboxylic acid derivatives according to the present invention are as follows ; 1. l-(3-fluoro-4-pyridyl )-6-fluoro-7-(1-piperazinyl)-l,4-dihydro-4-oxoquinoline-3- carboxylic acid 2. l-(3-fluoro-4-pyridyl)-6-fluoro-7-(4-methyl-l-piperazinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid 3. l-(3-fluorx)-4-pyridyl)-6-fluoro-7-(3-ιιethyl-l-piperazinyl)-l,4-dihyc-ro-4- 5 oxoquinoline-3-carboxylic acid 4. l-(3-fluoro-4-pyridyl)-6-fluoro-7-(3,5-diraethyl-l-piperazinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid 5. l-(3-fluoro-4-pyridyl)-6-fluoro-7-(3-amino-l-pyrrolidinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid 10 6. l-(3-fluoro-4-pyridyl)-6-fluoro-7-[(3S)-3-amino-l-pyrrolidinyl]-l,4-dihydro-4- oxoquinoline-3-carboxylic acid 7. l-(3-fluoro-4-pyτidyl)-6-fluoro-7-(l-piperazinyl)-l,4-dihydro-4-oxo-l,8- naphthyridine-3-carboxylic acid 8. l-(3-fluoro-4-pyridyl)-6-f]uoro-7-(4-methyl-l-piperazinyl)-l,4-dihydro-4-oxo-l,8 15 -naphthyridine-3-carboxylic acid 9. l-(3-fluoro-4-pyridyl)-6-fluorO-7-(3-methyl-l-piperazinyl)-l,4-dihydro-4-oxo-l,8 -naphthyridine-3-carboxylic acid 10. l-(3-fluoro-4-pyridyl)-6-fluoro-7-(3,5-diraethyl-l-pipera__inyl)-l,4-dihydro-4- oxo-l,8-naphthyridine-3-carboxylic acid 20 11. l-(3-fluoro-4-pyridyl)-6-fluoro-7-[(3S)-3-amino-l-pyrrolidinyl)-l,4-dihydro-4- oxo-1,8-naphthyridine-3-carboxylic acid 12. l-(5-fluoro-2-pyridy1)-6-fluoro-7-(1-piperazinyl)-l,4-dihydro-4-oxo-l,8- naphthyridine-3-carboxylic acid 13. l-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-l-piperazinyl)-l,4-dihydro-4-oxo- 25 l,8-naphthyridine-3-carboxylic acid 14. l-(5-fluoro-2-pj -idyl)-6-fluoro-7-(3-methyl-l-piperazinyl)-l,4-dihydro-4-oxo- 1,8-naphthyridine-3-carboxylie acid 15. l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3,5-diraethyl-l-piperazinyl)-l,4-dihydro-4- oxo-1,8-naphthyridine-3-carboxy]ic acid 30 16. l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3-amino-l-pyrrolidinyl)-l,4-dihydro-4-oxo- l,8-naphthyridine-3-carboxylic acid 17. l-(5-fluoro-2-pyridyl ) -6-fluoro-7-(l-piperazinyl)-l,4-dihydrc—4-oxoquinoline- 3-carboxylic acid 18. l-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-l-piperazinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid 19. l- ( 5-fluorc»-2-pyridyl)-6-fluoro-7-(3-methyl-l-pipera__inyl)-l,4-dihydro-4- oxoquino1ine-3-carboxylie acid 5 20. l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3,5-diraethyl-l-piperazinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid 21. l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3-amino-l-pyrrolidinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid 22. l-(5-fluoro-2-pyridyl)-6-fluoro-7-[(3S)-3-amino-l-pyrrolidinyl)-l,4-dihydro-4- 10 oxoquinoline-3-carboxylic acid 23. l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(1-piperazinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid 24. l-(5-fluoro-2-pyridyl)-6,8-difluorc—7-(4-methyl-l-piperazinyl)-l,4-dihydrc—4- oxoquinoline-3-carboxylic acid 15 25. l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(3-methyl-l-piperazinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid 26. l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(3,5-di_ιιethyl-l-piperazinyl)-l,4-dihydro- 4-oxoquinoline-3-carboxylic acid 27. l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(3-araino-l-pyrrolidinyl)-l,4~dihydro-4- 20 oxoquinoline-3-carboxylic acid 28. 5-methyl-7-(4-methyl-l-piperazinyl)-l-(5-fluoro-2-pyridyl)-6-fluoro-l,4-dihydro -4-oxoquinoline-3-carboxylic acid 29. 5-methyl-7-(3-methyl-l-piperazinyl)-l-(5-fluoro-2-pyridyl)-6-fluoro-1,4-dihydro -4-oxoquinoline-3-carboxylic acid 25 Meanwhile, the novel quinolone carboxylic acid derivatives according to this invention may be used as free compounds, acid addition salts thereof or salts of the carboxyl groups thereof. The suitable acids for salt formation include inorganic acids such as hydrochloric acid, phosphoric acid and organic acids such 30 as acetic acid, oxalic acid, succinic acid, methanesulfonic acid, maleic acid, malonic acid, gluconic acid. Pharmaceutically acceptable base salts of the above described compounds of the formula (I) are formed with alkali metals such as sodium, potassium or alkaline earth metals such as magnesium, calcium. The free compounds of the present invention, their acid addition salts and their salts of the carboxyl groups of pyridone carboxylic acid derivatives may exist as hydrates. The following examples are provided to illustrate the desirable preparation of the compounds of the present invention. Preparation 1 Preparation of ethyl 3-(3-fluoro-4-pyridyl)amino-2-(2,4,5-trifluorobenzoyl)aerylate 2.5g of ethyl 2,4,5-trifluorobenzoyl acetate, 2.55ml of triethyl o-formate, 12ml of acetic anhydride are mixed together and refluxed for 3 to 5 hours, cooled to room temperature, and distilled under a reduced pressure. The obtained product is dissolved in 50ml of anhydrous dichloromethane and added with 1.26g of 4-amino—3-fluoropyridine and stirred at room temperature for 5 hours, and then concentrated under a reduced pressure. The product is used in the next reaction without further purification. Preparation 2 Preparation of ethyl 3-(3-fluoro-4-pyridyl)amino-2-(2,6-dichloro-5-fluoronicotinyl) aerylate A procedure substantially similar to the procedure in Preparation 1 is carried out to prepare the title compound. Preparation 3 Preparation of ethyl 3-(5-fluoro-2-pyrid l)amino-2-(2,6-dichlore—5-fluoronicotinyl) aerylate A procedure substantially similar to the procedure in Preparation 1 is carried out to prepare the title compound. Preparation 4 Preparation of ethyl 3-(5-fluoro-2-pyτidyl )amino-2-(2,3,4,5-tetrafluorobenzoyl ) aerylate A procedure substantially similar to the procedure in Preparation 1 is carried out to prepare the title compound. Preparation 5 Preparation of ethyl 3-(5-fluoro-2-pyridyl)amino-2-(2,4,5-trifluorobenzoyl)acrylate A procedure substantially similar to the procedure in Preparation 1 is carried out to prepare the title compound. Preparation 6 Preparation of ethyl 3-(5-fluoro-2-pyridyl)amino-2-(3-methyl-2,4,5-trifluorobenzoyl )aerylate A procedure substantially similar to the procedure in Preparation 1 is carried out to prepare the title compound. Preparation 7 Preparation of ethyl l-(3-fluorχj-4-pyridyl)-6,7-difluoro-l,4-dihydro-4-oxoquinoline -3-carboxy1ate 2.0g of ethyl 3-(3-fluoro-4-pjτidy])amino-2-(2,4,5-trifluorobenzoyl)acrylate, 1.50g of potassium carbonate and 0.43g of 18-crown-6 are mixed with 40ml of anhydrous acetonitrile. The mixture is refluxed for 3 hours and then cooled, added with 100ml of water and stirred during 30 minutes, then filtered and dried to obtain 1.3g of the desired compound. m.p. : 212°C i H-NMRfCDCls, ppm ) : 1.26 (t,3H,J=7.20Hz), 4.40(q,2H, =7.20Hz), 6.50-6.80 ( m,lH), 7.40-7.60(m,lH), 8.22-8.42(m,2H), 8.68-8.96(m,2H) Preparation 8 Preparation of ethyl l-(3-fluoro-4-pyridyl)-6-fluoro—7-chloro-l,4-dihydro-4-oxo-l,8 -naphthyridine-3-carboxylate A procedure substantially similar to the procedure in Preparation 7 is carried out to prepare the title compound. m.p. : 226 * C 1 H-NMR(CDC1 3 , ppm) : 1.42 (t,3H,J=7.20Hz), 4.42(q,2H, =7.20Hz), 7.46-7.50(m,1H), 8.48-8.54(m,2H), 8.70-8.82(m,2H) Preparation 9 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6-fluoro-7-chloro-l,4-dihydro-4-oxo-l,8 -naphthyridine-3-carboxylate A procedure substantially similar to the procedure in Preparation 7 is carried out to prepare the title compound, m.p. : 230"C i H-NMRfCDCla, ppm) : 1.36 (t,3H,J=7.20Hz), 4.38(q,2H,J=7.20Hz), 7.60-7.80(m,2H), 8.36-8.54(m,2H), 8.94(s,lH) Preparation 10 Preparation of ethyl 1—(5-fluoro-2-pyridyl)-6,7-difluoro-l,4-dihydro-4-oxoquinoline -3-carboxy1ate A procedure substantially similar to the procedure in Preparation 7 is carried out to prepare the title compound. m.p. : 210-213'C 1 H-NMR(CDC1 3 , ppm ) : 1.50 (t,3H,J=8.00Hz), 4.70(q,2H,J=8.00Hz), 7.42(dd,lH, J=3.04Hz,J=10.04Hz), 7.92-8.19(m,2H), 8.50-8.79(m,2H), 9.45(s,lH) Preparation 11 Preparation of ethyl l-(5-fluorc-2-pyridyl)-6,7,8-trifluoro-l,4-dihydro-4- oxoquinoline-3-carboxylate A procedure substantially similar to the procedure in Preparation 7 is carried out to prepare the title compound. m.p. : 203-205°C 'H-NMRtCDCls, ppm ) : 1.32 (t,3H,J=7.20Hz), 4.32<q,2H, =7.20Hz), 7.36-7.72(m,2H), 8.00-8.22(m,lH), 8.30-8.50(m,2H) Preparation 12 Preparation of l-(3-fluoro-4-pyridyl ) -6,7-difluoro-l,4-dihydro-4-oxoquinoline-3- carboxylic acid 5g of ethyl l- ( 3-fluoro-4-pyridyl)-6,7-difluoro-l,4-dihydro-4-oxoquinoline-3- carboxylate is added with 20ml of water, 30ml of ethanol and 15 ml of cone. hydrochloric acid and refluxed for 8 hours. After cooling to room temperature and standing for 2 hours, filtering and drying are carried out to obtain 4.2g of the desired compound, m.p. 271-273°C ^-NMRfCFaCOOD, ppm) : 7.28-7.58(ra,lH), 8.26-8.88(m,2H), 9.22-9.62(m,3H) Preparation 13 Preparation of l-(3-fluoro-4-pyridyl)-6-fluoro-7-chloro-l,4-dihydro-4-oxo-l,8- naphthyridine-3- carboxylic acid A procedure substantially similar to the procedure in Preparation 12 is carried out to prepare the title compound. m.p.: 228-230T. *H NMR(CDC1 3 , ppm ) : 8.50-8.74(m,2H), 9.16-9.42(m,3H) Preparation 14 Preparation of l-(5-fluoro-2-pyridyl)-6,7-difluoro-1,4-dihydro-4-oxoquinoline-3- carboxylic acid A procedure substantially similar to the procedure in Preparation 12 is carried out to prepare the title compound. m.p.: 275-280 * C *H NMR(CF 3 C00D, ppm) : 7.40(dd,lH,J=3.02Hz, =10.06Hz), 7.92-8.18(m,2H), 8.39-8.78(m,2H), 9.50(s,lH) Preparation 15 Preparation of l-(5-fluoro-2-pyridyl)-6-fluoro-7-chloro-l,4-dihydro-4-oxo-l,8- naphthyridine-3-carboxylic acid A procedure substantially similar to the procedure in Preparation 12 is carried out to prepare the title compound. m.p.: 234-238T. H NMR(CDC1 , ppm) : 8.58-8.84(m,2H) , 9.18-9.42(m,3H) Preparation 16 Preparation of ethyl 1-(5-f1uorc-2-pyridy1)-6-f1uorc—7-(1-piperaziny1)-1,4- 5/ 12 dihydro-4-oxo-l,8-naphthyridine-3-carboxylate 0.5g of ethyl l-(5-fluorc~2-pyridyl)-6-fluoro-7--chloro-l,4-dihydro-4--oxo-l,8- naphthyridine-3-carboxylate and 0.35g of piperazine are added to 45ml of pyridine. The mixture is stirred at lO'C for 1 hour and then concentrated under a reduced pressure and subjected to a column chromatography (acetone/n-hexane=5/2) to obtain 0.47g of the desired compound, which is then subjected to the next reaction to identify its structure, (next reaction : Example 12) Preparation 17 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-l-piperazinyl)- 1,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 85.0% Preparation 18 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6- luoro-7-(3-methyl-l-piperazinyl ) - 1,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 91.5% Preparation 19 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6-fluorc—7-(3,5-dimethyl-l-piper__zinyl) -1,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 84.1% m.p. : 165 * 0 »H NMR(CDC1 3 , ppra) : 0.94(s,3H), 1.00(s,3H), 1.35(t,3H, =6.40Hz), 2.24-3.06(m,4H), 4.00-4.42(m,4H), 7.44-8.24(m,3H), 8.38-8.52(m,1H), 8.76(s,lH) Preparation 20 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3-acetamido-l-pyrrolidinyl ) -1,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylate A procedure substantially siailar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 90.3% m.p. : 200-202 * C J -H NMR(CDC1 3 , ppm) : 1.30(t,3H,J=6.40Hz>, 1.90-2.16(m,5H), 3.40-3.94(ra,4H), 4.28(q,2H,J=6.40Hz ) , 4.76(m,lH), 7.44-8.06(m,3H), 8.32-8.46(m,lH , 8.68(s,lH) Preparation 21 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(l-piperazinyl)-l,4- dihydro-4-oxoquinoline-3-carbox late A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 90.3% Preparation 22 Preparation of ethyl l-(5-f]uoro-2-pyridyl)-6,8-difluoro-7-(4-methyl-l-piperazinyl ) -1,4-dihydro-4-oxoquinoline-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 91.3% Preparation 23 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(3-methyl-l-piperazinyl) -1,4- dihydro-4-oxoquinoline-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 87.5% Preparation 24 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(3,5-dimethyl-l- piperazinyl )-l,4- dihydro-4-oxoquinoline-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 89.3% Preparation 25 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(3-acetaraidc—l- pyrrolidinyl)-l,4- dihydro-4-oxoquinoline-3- carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out. to prepare the title compound. Yield : 90.3% Preparation 26 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6-fluoro-7-(l-piperazinyl)-l,4-dihydro -4-oxoquinoline-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 84.5% Preparation 27 Preparation of ethyl l-(5-fluoro-2-pyridyl )-6-fluoro-7-(4-methyl-l-piperazinyl)-l,4 -dihydro-4-oxoquinoline-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 88.7% Preparation 28 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6-fluoro-7- ( 3-methyl-l-piperazinyl>-1.4 -dihydro-4-oxoquinoline-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 83.7% Preparation 29 Preparation of ethyl l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3,5-dimethyl-l-piperazinyl) -1,4-dihydrc—4-oxoquinoline-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 88.7% Preparation 30 Preparation of ethyl l-(5-fluorc-2-pyridyl)-6-fluoro—7-(3-acetamido-l-pyrrolidinyl) -1,4-dihydrc-4-oxoquinoline-3-carboxylate A procedure substantially similar to the pιrχ.edure in Preparation 16 is carried out to prepare the title compound. Yield : 92.7% Preparation 31 Preparation of l-(. -f]uoro-4-pyridyl)-6-fluoro-7-(3-acetaraido-l-pyrrolidinyl)-l,4- dihydro-4-oxoquinoline-3-carboxylic acid 0.22g of l-(3-fluoro-4-pyridyl)-6,7-difluoro-l,4-dihydro-4-oxoquinoline-3- carboxylic acid and 0.llg of 3-acetamidopyrrolidine are added to 12ml of pyridine, and added with 0.13ml of l,8-diazabicyclo[5.4.0]undec-7-ene. The mixture is stirred at room temperature for 24 hours, and then concentrated under a reduced pressure to remove the solvent completely. The residue is added with 20ml of acetone and stirred at room temperature for 1 hour to obtain a product, which is then filtered and dried and used in the next reaction, (next reaction : Example 5) Preparation 32 Preparation of ethyl 5-methyl- 7-(4-methyl-l-piperazinyl)-l-(5-fluoro-2-pyridyl)-6- fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 82.5% Preparation 33 Preparation of ethyl 5-methyl-7-(3-methyl-l-piperazinyl)-l-(5-fluoro-2-pyridyl)-6- fluorc-1,4-dihydro-4-oxoquinoline-3-carboxylate A procedure substantially similar to the procedure in Preparation 16 is carried out to prepare the title compound. Yield : 85.0% Example 1 Preparation of l-(3-fluoro-4-pyridyl)-6-fluoro-7-(1-piperazinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid hydrochloride 0.66g of l-(3-fluoro-4-pyridyl)-6,7-difluoro-1,4-dihydro-4-oxoquinoline-3- carboxylic acid and 0.22mg of piperazine are added to 30ml of pyridine. The mixture is added with 0.39ml of l,8-diazabicyclo[5.4.0]undec-7-ene, stirred at. room temperature for 24 hours and concentrated under a reduced pressure. The concentrate is subjected to a column chromatography(chloroform/methanol/ammonia water=l5/12/1) to seperate the desired product, which is then concentrated under a reduced pressure. After then, the residue is added with 15ml of ethanol, 10ml of water and 5ml of cone, hydrochloric acid and stirred at room temperature for 3 hours, filtered and dried. The obtained product is recrystallized in a mixed solvent of methanol or ethanol and water to obtain 0.47g of the desired compound, m.p.: 284-286 * C(dec. ) --H NMR(CF 3 C00D, ppm) : 3.26-4.24(m,8H), 6.84(d,lH,J=4.82Hz), 8.38(d.lH,J=12.82Hz), 8.70-9.02(m,lH), 9.20-9.62(m,3H) Example 2 Preparation of l-(3-fluoro-4-pyridyl)-6-fluoro-7-(4-methyl-l-piperazinyl)-l,4- dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 1 is carried out to prepare the title compound. m.p. : 274-276°C(dec.) *H NMR(CF 3 C0QD, ppm) : 3.12(s,3H), 3.28-4.32(ra,8H), 6.88(d,lH,J=4.80Hz), 8.38(d,lH,J=12.80Hz), 8.68-8.98(m,1H), 9.20-9.60(m,3H) Example 3 Preparation of l-(3-f luoro-4-pyridyl )-6-f luoro— 7-(3-raethyl-l-piperazinyl )-l , 4- dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 1 is carried out to prepare the title compound. m.p. : 270-272 Φ C(dec.) J H NMR(CF 3 C00D, ppm) : 1.52(d,3H,J=5.62Hz), 3.36-4.24(m,7H), 6.86(d,lH,J=4.80Hz), 8.36(d,lH,J=12.80Hz), 8.70-8.92(m,1H), 9.26-9.60(m,3H) Example 4 Preparation of l-(3-fluoro-4-pyridyl)-6-fluoro-7-(3,5-difflethyl-l-piperazinyl)-l,4- dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 1 is carried out to prepare the title compound. m.p. : 285-287°C(dec.) *H NMR(CF 3 C0OD, ppm) : 1.38-1.62(ra,6H), 3.20-4.28(m,6H), 6.90(d,lH, =4.80Hz), 8.38(d,lH,J=12.80Hz), 8.68-9.00(m,lH), 9.20-9.56(m,3H) Example 5 Preparation of l-(3-fluoro-4-pyridyl)-6-fluoro-7-(3-amino-l-pyrrolidinyl)-l,4- dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride 0.5g of l-(3-fluoro-4-pyridyl)-6-fluoro-7-(3-acetamidc-l-pyrrolidyl)-l,4- dihydro—4-oxoquinoline-3-carboxylic acid is added to 15ml of ethanol, 10ml of water and 5ml of cone, hydrochloric acid. The reaction mixture is refluxed for 18 hours, cooled and concentrated under a reduced pressure to remove the solvent completely. The residue is recrystallized in a mixed solvent of ethanol and water to obtain 0.22g of the desired compound. m.p.: 274-276°C(dec.) J H NMR(CF 3 C00D, ppm) 2.38-2.70(m,2H), 3.60-4.08(m,2H), 4.10-4.52(m,3H), 6.24(d,lH.J=4.80Hz), 8.22(d,lH,J=12.82Hz), 8.68-9.00(m,lH), 9.16-9.60(m,3H) Example 6 Preparation of l-(3-fluoro-4-pyridyl)-6-fluoro-7-[(3S)-3-amino-l-pyrrolidinyl]-l,4- dihydro-4-oxoquinoline-3-carboxylic acid A procedure substantially similar to the procedure in Example 1 is carried out to prepare the title compound. m.p. : 225-227T <dec. ) J H NMR(CF 3 C00D, ppm) : 2.38-2.72(ra,2H), 3.60-3.98(m,2H), 4.18-4.60(m,3H), 6.26(d,lH,J=4.80Hz), 8.28(d,lH, =12.82Hz), 8.58-8.84(m,1H ) , 9.12-9.52(m,3H) Example 7 Preparation of l-(3-fluoro-4-pyridyl)-6-fluoro-7-(1-piperazinyl)-l,4-dihydro-4-oxo -l,8-naphthyridine-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 1 is carried out to prepare the title compound, m.p. : 273-275C(dec.) *H NMR(CF 3 C00D, ppm) : 3.42-4.60(m,8H), 8.32(d,lH,J=12.02Hz), 8.60-8.86(m,lH), 9.10-9.58(m,3H) Example 8 Preparation of l-(3-fluoro-4-pyridyl )-6-fluoro-7-(4-methyl-l-piperazinyl)-l,4- dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 1 is carried out to prepare the title compound, m.p. : 275°C J H NMR(CF 3 C00D, ppm) : 3.10(s,3H), 3.14-4.10(m,6H). 4.26-4.92(m,2H), 8.30 ( d,lH,J=12.00Hz), 8.60-8.88(m,lH), 9.20-9.50(m,3H) Example 9 Preparation of l- ( 3-fluoro-4-pyridyl)-6-fluorc—7-(3-methyl-l-piperazinyl)-l,4- dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 1 is carried out to prepare the title compound. m.p. : 277-279'C(dec. ) ' ti NMR(CF 3 C0OD, ppm) : 1.32-1.68(m,3H), 3.32-4.08(m,5H), 4.34-4.84(m,2H), 8.32(d,lH,J=12.02Hz), 8.60-8.90(m,lH), 9.20-9.50(m,3H) Example 10 Preparation of l-(3-fluoro-4-pyridyl)-6-fluoro-7-(3,5-dimethyl-l-piperazinyl)-l,4- dihydrc—4-oxo-l,8-naphthjτidine-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 1 is carried out to prepare the title compound, m.p. : 270°C(dec.) *H NMR(CF 3 C0OD, ppm) : 1.30-1.60(ra,6H), 3.32-3.92(m,4H), 4.44-4.92(m,2H), 8.36(d,lH,J=12.02Hz), 8.62-8.90(m,lH), 9.16-9.52(m,3H) Example 11 Preparation of l-(3-fluoro-4-pyridyl)-6-fluoro-7-[(3S)-3-amino-l-pyrrolidinyl]-l,4- dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 1 is carried out to prepare the title compound. m.p. : 269 < C *H NMR(CF 3 C00D, ppm) : 2.14-2.84(n,2H), 3.56-4.64(m,5H), 8.23(d,lH, =12.04Hz), 8.62-8.96(m,lH), 9.10-9.52(m,3H) Example 12 Preparation of l-(5-fluorc—2-pyridyl)-6-fluoro-7-(l-piperazinyl)-l,4-dihydrc-4-oxo -l,8-naphthyridine-3-carboxylic acid hydrochloride 0.5g of ethyl l-(5-fluoro-2-pyridyl)-6-fluoro-7-(l-piperazinyl)-l,4-dihydro-4- oxo-l,8-naphthyridine-3-carboxylate is added to 10ml of water and 10ml of cone, hydrochloric acid. The mixture is refluxed for 24 hours, cooled to room temperature and concentrated under a reduced pressure. The concentrate is added with 20ml of ethanol and stirred at room temperature for 2 hours, filtered and dried. The product is recrystallized in a mixed solvent of water and methanol to obtain 0.39g of the desired compound, m.p.: >300°C »H NMR(CF 3 C0OD, ppm) : 3.60-3.80(m,4H), 4.14-4.46(m,4H), 7.92-8.50(m,3H), 8.70(bs,lH), 9.40(s,lH) Example 13 Preparation of l-(5-fluoro-2-pyridyl)-6-fluoro-7-(4-methyl-l-piperazinyl)-l,4- dihydro-4-oxo-1.8-naρhthyridine-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound. m.p. : 275-277T, J H NMR(CF 3 C00D, ppm) : 3.10(s,3H), 3.60-5.00(m,8H), 7.84-8.50(m,3H), 8.68(bs,lH), 9.38(s,lH) Example 14 Preparation of l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3-methyl-l-piperazinyl)-l,4- dihydro-4-oxo-l,8-naphthyridine-3-carboxy1ic acid hydroch1oride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound, m.p. : 268 c C(dec.) --H NMR.CFsCOOD, ppm) : 1.40-1.60(ra,3H), 3.50-3.90(m,5H), 4.56-4.80(m,2H), 8.12-8.46(m,3H), 8.74(bs,lH), 9.40(s,lH) Example 15 Preparation of l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3,5-dimethyl-l-piperazinyl)-l,4- dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound, m.p. : 289°C(dec.) »H NMR(CF 3 C00D, ppm) : 1.30-1.64(m,6H), 3.28-4.00(m,4H), 4.52-4.92(m,2H) , 7.96-8.48(m,3H), 8.78(bs,lH), 9.40(s,lH) Example 16 Preparation of l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3-amino-l-pyrrolidinyl)-l,4- dihydro-4-oxo-l,8-naphthyridine-3-carboxylic acid hydrochloride 0.5g of ethyl l-(5-fluoro-2-pyridyl)-6-fluoro-7-(acetamido-l-pyrrolidinyl )- l,4-dihydro-4-oxo-l,8-naphthyridine-3-carboxylate is added to 10ml of water and 10ml of cone, hydrochloric acid. The mixture is refluxed for 24 hours, cooled to room temperature and concentrated under a reduced pressure. The concentrate is added with 20ml of ethanol and dissolved completely. After then. 70ml of ethvl ether is added for precipitation, and then stirred at room temperature for 2 hours, filtered and dried. The product is recrystallized in a mixed solvent of methanol and water to obtain 0.35g of the desired compound m.p. : 208-210°C *H NMR(CF 3 C00D, ppm) : 2.30-2.80(m,2H), 3.78-4.68(m,5H), 7.96-8.32(m,3H), 8.70(bs,lH), 9.32(s,lH) Example 17 Preparation of l-(5-fluoro-2-pyridyl)-6-fluoro-7-(l-piperazinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound, m.p. : 300°C(dec. ) *H NMR.CF3COQD, ppm) : 3.51-4.05(m,8H), 6.80(d,lH,J=7.60Hz), 7.84-8.21(m,2H), 8.32(d,lH,J=12.04Hz), 8.70(bs,lH) 9.30(s,lH) Example 18 Preparation of l-(5-fluorc—2-pyridyl)-6-fluoro-7-(4-methyl-l-piperazinyl)-l,4- dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound, m.p. : > 300°C(dec.) *H NMR(CF 3 C00D, ppm) : 3.12(s,3H), 3.28-4.29(m,8H), 6.81(d,lH,J=7.60Hz), 7.84-8.15(m,2H), 8.33(d,1H, =12.20Hz), 8.71(bs,lH), 9.29(s,lH) Example 19 Preparation of l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3-methyl-l-piperazinyl)-l,4- dihydrc—4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound, m.p. : 295 * C(dec.) »H NMR(CF 3 C00U, ppm) : 1.51(d.3H. =4.40Hz), 3.23-4.ll(m,7H). 6.80(d,lH.J=6.20Hz), 7.96-8.16(ra,2H), 8.30(d.lH, =14.00Hz), 8.69(s,lH), 9.30 ( s,lH ) Example 20 Preparation of l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3.5-dimethyl-l-piperazinyl)-l,4- dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound. m.p. : 297"C(dec.) »H NMR.CFsCOOD, ppm) : 1.30-1.65(m,6H), 3.10-4.57(m,6H), 6.89(d,lH, =6.20Hz), 7.93-8.20(m,2H), 8.70(d,lH, =12.82Hz), 8.48(s,lH), 9.32(s,lH) Example 21 Preparation of l-(5-fluoro-2-pyridyl)-6-fluoro-7-(3-amino-l-pyrrolidinyl ) -l,4- dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 16 is carried out to prepare the title compound. m.p. : 275°C(dec.) *H NMRICFsCOOD. ppm) : 2.40-2.73(ra.2H), 3.60-4.56(m,5H). 6.33(d,lH, =6.20Hz), 7.98-8.37(m,3H), 8.75(s,lH). 9.24(s.lH) Example 22 Preparation of l-(5-fluoro-2-pyridyl)-6-fluoro-7-[ ( 3S)-3-amino-l-pyrrolidinyl.]-1.4 -dihydro-4-oxoquinoline-3-carboxylic acid hvdrochloride A procedure substantially similar to the procedure in Example 1 is carried out to prepare the title compound, m.p. : 268-272T'.(dec. ) i H NMR(CF 3 C00D. ppm) : 2.40-2.73(m.2H), 3.60-4.56(m,5H). 6.33(d.lH,J=6.20Hz), 7.98-8.37(m,3H). 8.75(s.lH). 9.24(s.lH) Example 23 Preparation of l-(5-fluoro-2-pyridyl )-6,8-iifluoro-7-(1-piperazinyl)-1.4-dihydro- 4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound. m.p. : 300'C(dec.) *H NMR(CF 3 C00D, ppm) : 3.76-4.02(ra.8H). 8.00-8.48(m,3H). 8.68(bs,lH), 9.32(s,lH) Example 24 Preparation of l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(4-methyl-l-ρiperazinyl )-l,4- dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound, m.p. : 247°C(dec.) *H NMR<CF 3 C00D, ppm) : 3.10(s,3H), 3.20-4.00(ra,8H), 7.98-8.38(m.3H), 8.58(bs,lH), 9.30(s,lH) Example 25 Preparation of l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(3-methyl-l-piperazinyl )-l,4- dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound, m.p. : 295°C(dec.) *H NMR(CF 3 C00D, ppm) : 1.45-1.60(d,3H, =3.20Hz), 3.38-4.02(m,7H), 7.92-8.50(m,3H), 8.70(bs,lH), 9.30(s,lH) Example 26 Preparation of l-(5-fluoro-2-pyridyl)-6,8-difluoro-7-(3,5-dimethyl-l-piperazinyl ) - l,4-dihydro-4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound, m.p. : 297"C(dec.) J H NMR(CF 3 C00D, ppm) : 1.32-1.60(m,6H), 3.38-3.90(m,6H ) , 7.96-8.41(m,3H ) . 8.64(bs,lH), 9.32(s,lH) Example 27 Preparation of 1—(5-fluorc-2-pyridyl )-6,8-difluoro-7-(3-ammo-l-pyrrolidinvl ) -l,4 -dihvdro-4-oxoquinoline-3-carboxylic acid hvdrochloride A procedure substantially similar to the procedure in Example 16 is carried out to prepare the title compound, m.p. : 275°C(dec.) J H NMRfCF.COOD. ppm) : 2.40-2.60(m,2H), 3.98-4.24(m,5H), 8.08-8.38 ( m,3H), 8.64(s,lH), 9.24(s.lH> Example 28 Preparation of 5-methyl-7-(4-methyl-l-pipera_inyl)- l-(5-fluoro-2-pyridyl)-6- fluoro-1.4-dihvdro-4-oxoquinoline-3-carboxylic acid hydrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound. m.p. : 262 <> C(dec.) *H NMR(CF 3 C00D, ppm) : 2.99(s,3H), 3.10(s,3H), 3.15-4.20(ra,8H), 6.60(d,lH,J=7.20Hz), 8.02(m,2H), 8.70<s,lH), 9.24(s,lH ) Example 29 Preparation of 5-methyl-7-(3-methyl-l-piperazinyl)-l-(5-fluoro-2-pyridyl)-6-fluoro -l,4-dihvdro-4-oxoquinoline-3-carboxvlic acid hvdrochloride A procedure substantially similar to the procedure in Example 12 is carried out to prepare the title compound. m.p. : 276 c C<dec.) *H NMR(CF 3 C00D, ppm) : 1.60(d,3H.J=6.00Hz), 2.97(s,3H), 3.15-4.21(m.7H), 6.60(d,lH,J=8.00Hz), 8.40(m,2H), 8.65(s,lH), 9.25(s,lH) The in vitro antibiotic activity of the present compound is measured using 2-fold dilution method with a micro-well plate and the bacteria are inoculated in about 10 5 cfu/ml after an overnight culture in a brain-heart infusion(BHI) broth at 37'C The novel compounds of the present invention are converted to a hvdrochloride salt form and diluted with a sterilized distilled water to make lOmg/ml aqueous solution. After the mother liquor wherein the compound is diluted to the two-fold concentration has been obtained in the form of an aqueous solution, the respective O.lml of diluted liquor is transferred to a well and is inoculated with O.lral of the culture fluid to make about (10 5 -10 6 )/2 cfu/ml. After cultivation at 37'C, the minimum inliibitory concentration(MIC) is measured and recorded in Table I-V. Table I - V show the minimum inhibitory concentrations(MIC). Table I. Minimum Inhibitory Concentration lye/ml ) Table II. Minimum Inhibitory Concentration .μg/ml ) Table III. Minimum Inhibitorv Concentration (ug/al ) Table IV. Minimum Inhibitory Concentration (μg/ml) Table V. Minimum Inhibitory Concentration (/.g/ml 31 The followings are the original names for strains in Table I - V. Acinetobacter calcoaceticus ATCC 19606 Citrobacter freundii ATCC 8090 Enterobacter aerogenes ATCC 13048 Enterobacter cloacae ATCC 23355 Escherichia coli ATCC 25922 Haemophilus influenza ATCC 35056 Klebsiella pneumoniae ATCC 13883 Proteus vulgaris ATCC 13315 Pseudoraonas aeruginosa ATCC 27853 Salmonella typhimurium ATCC 14028 Shigella flexneri ATCC 12022 Shigella sonnei ATCC 25931 Serratia marcescens ATCC 8100 Streptococcus faecalis ATCC 19433 Streptococcus faecalis ATCC 29212 Streptococcus pneumoniae ATCC 6303 Streptococcus pyrogens ATCC 19615 The pharmacokinetic properties are tested by orallv administrating and subcutaneously injecting a test compound and a substance for control to a ICR Mouse with 22g±10% weight, drawing blood after 10, 20, 30, 45, 60, 90, 120, 150, 180 and 240 minutes and analyzed by Bio-Assay(Agar well method). The average values from four tests for each compound are recorded in the following Table VI. Table VI. The LDso of example 13 was about l,000g/kg and example 18 about > 3,000g/kg. (Oral, mice)

Claims: CLAIMS What is claimed is : 1. Quinolone carboxylic acid derivatives of the formula (I), their pharmaceutically acceptable salts and their hydrates. Wherein X is a hydrocarbon, fluorocarbon or nitrogen atom, Y is a hydrogen or methyl group, R 1 is a hydrogen or alkyl group having 1 to 5 carbon atom, R 2 B is a fluorocarbon or nitrogen that, if A=CF, B=N and if A=N, R 3 (wherein R 4 is an amino group which makes a racemate or (S)-enantiomer) or / ' V π (wherein R 5 , R 6 and R 7 are respectively hydrogen or —' alkyl group having 1 to 3 carbon atom.). 2. The compound as claimed in claim 1. corresponding to the following formula (IA), wherein R 3 is piperazine derivatives wherein X, Y, R 1 , R 2 , R 5 , R 6 and R 7 are each as defined in the claim 1. 3. The compound as claimed in claim 1, corresponding to the following formula (IB), wherein R 3 is pyrolidine derivatives wherein X, Y, R 1 , R 2 and R 4 are each as defined in the claim 1. 4. l-(5-fluoro -2-pyridyl )-6-fluoro-7-(4-methyl-l-piperazinyl)-l,4-dihydrc—4-oxo- l,8-naphthyridine-3-carboxylic acid, according to claim 2. 5. l-(5-fluoro-2-pyridyl )-6-fluoro-7-(3-methyl-l-piperazinyl)-l,4-dihydro-4-oxo- l,8-naphthyridine-3-carboxylic acid, according to claim 2. 6. l-(5-fluoro-2-pyridyl )-6-fluoro-7-(4-methyl-l-piperazinyl)-l,4-dihydro-4- oxoquinoline-3-carboxylic acid, according to claim 2. 7. l-(5-fluoro-2-pyridyl )-6-fluoro-7-(3-raethyl-l-piperazinyl ) -l,4-dihydro-4- oxoquinoline-3-carboxylic acid, according to claim 2. 8. 5-methyl-7-(4-methyl-l-piperazinyl)-l-(5-fluoro-2-pyridyl )-6-fluoro-l,4-dihydro- 4-oxoquinoline-3-carboxylic acid, according to claim 2. 9. 5-methyl-7-(3-methyl-l-piperazinyl)-l-(5-fluoro-2-pyridyl )-6-fluoro-l,4-dihydro- 4-oxoquinoline-3-carboxylic acid ' , according to claim 2. 10. l-(3-fluoro-4-pyridyl )-6-fluoro-7-[(3S)-3-amino-l-pyrrolidinyl]-l,4-dihydro-4- oxoquinoline-3-carboxylic acid, according to claim 3. 11. l-<5-fluoro-2-pvridy1 )-6-fluoro-7-T(3S)-3-araino-l-pyrrolidinyl]-l.4-dihydro-4- oxoquinoline-3-carboxylic acid, according to claim 3. 12. A process for preparing the compound of the formula (I) and its pharmaceutically acceptable salts, which comprises the condensation of the compound of the formula (II) and the compound of the formula (VI) in a solvent in the presence of an acid-acceptor (II) (VI) (I) wherein X, Y, Z, R 1 , R 2 and R 3 are each as described in the claim 1. 13. The process according to claim 12, wherein the acid-acceptor is selected from the group consisting of tertiary amines including pyridine, triethylamine and l,8-diazabicyclo[5.4.0]undec—7-ene and alkali metal carbonates including potassium carbonate, or an excess of the compound of the formula (VI) which is a reactant; and the solvent is selected from the group consisting of pyridine, acetonitrile and N.N-dimethylformamide; and the reaction mixture consisting of 1 to 3 mo1 of the compound of the formula(VI) per 1 raol of the compound of the formula (II) is subjected to a condensation at a temperature from 0°C to 150°C depending on the kind of the mother nucleus.

Inventors: CHOI DONG RACK, CHUNG YONG HO, KIM NAM DOO, LEE CHI WOO, OH YOON SEOK, YOON SUNG JUNE, CHOI, DONG, RACK, CHUNG, YONG, HO, KIM, NAM, DOO, LEE, CHI, WOO, OH, YOON, SEOK, YOON, SUNG, JUNE
Applicants: DONG WHA PHARM IND CO LTD, DONG WHA PHARMACEUTICAL INDUSTRIAL CO., LTD.
Application year: 1994
Main classification: C07D401
IPC codes: A61K31, A61P31, C07D401, C07D471